PL2907521T3 - Nowe mutanty prongf i ich zastosowania w wytwarzaniu beta-ngf - Google Patents

Nowe mutanty prongf i ich zastosowania w wytwarzaniu beta-ngf

Info

Publication number: PL2907521T3
Authority: PL; Poland
Prior art keywords: ngf; beta; production; prongf mutants; novel
Prior art date: 2011-12-19

Application number

PL15157320T

Other languages

English (en)

Inventor

Susan Lorey

Bernhard Janowski

Heiko PULTKE

Daniela KATHMANN

Antje PARTHIER

Andreas Anton

Original Assignee

Wacker Chemie Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-12-19

Filing date

2012-12-19

Publication date

2018-04-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47428641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2907521(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-12-19 Application filed by Wacker Chemie Ag filed Critical Wacker Chemie Ag

2018-04-30 Publication of PL2907521T3 publication Critical patent/PL2907521T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Ophthalmology & Optometry (AREA)
Analytical Chemistry (AREA)
Crystallography & Structural Chemistry (AREA)
Epidemiology (AREA)
Immunology (AREA)
Psychology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL15157320T 2011-12-19 2012-12-19 Nowe mutanty prongf i ich zastosowania w wytwarzaniu beta-ngf PL2907521T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP11194208		2011-12-19
EP15157320.1A EP2907521B1 (en)	2011-12-19	2012-12-19	Novel prongf mutants and uses thereof in the production of beta-ngf
EP12805695.9A EP2672984B1 (en)	2011-12-19	2012-12-19	Novel prongf mutants and uses thereof in the production of beta-ngf

Publications (1)

Publication Number	Publication Date
PL2907521T3 true PL2907521T3 (pl)	2018-04-30

Family

ID=47428641

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL12805695T PL2672984T3 (pl)	2011-12-19	2012-12-19	Nowe mutanty PRONGF i ich zastosowanie do wytwarzania BETA-NGF
PL15157320T PL2907521T3 (pl)	2011-12-19	2012-12-19	Nowe mutanty prongf i ich zastosowania w wytwarzaniu beta-ngf

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL12805695T PL2672984T3 (pl)	2011-12-19	2012-12-19	Nowe mutanty PRONGF i ich zastosowanie do wytwarzania BETA-NGF

Country Status (27)

Country	Link
US (3)	US9617322B2 (pl)
EP (2)	EP2672984B1 (pl)
JP (4)	JP6039146B2 (pl)
KR (2)	KR101837802B1 (pl)
CN (2)	CN109400693A (pl)
AU (1)	AU2012357052B2 (pl)
BR (1)	BR112014014913B1 (pl)
CA (1)	CA2859262C (pl)
CY (2)	CY1117016T1 (pl)
DK (2)	DK2907521T3 (pl)
EA (1)	EA031333B1 (pl)
ES (2)	ES2545701T3 (pl)
HR (2)	HRP20150900T1 (pl)
HU (2)	HUE027245T2 (pl)
IL (1)	IL233137A0 (pl)
LT (1)	LT2907521T (pl)
MX (2)	MX370861B (pl)
NO (1)	NO2907521T3 (pl)
PL (2)	PL2672984T3 (pl)
PT (2)	PT2672984E (pl)
RS (2)	RS54220B1 (pl)
SG (2)	SG11201402585PA (pl)
SI (2)	SI2672984T1 (pl)
SM (2)	SMT201800097T1 (pl)
TR (1)	TR201802360T4 (pl)
WO (1)	WO2013092776A1 (pl)
ZA (1)	ZA201403753B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2672984T3 (pl) *	2011-12-19	2015-10-30	Wacker Chemie Ag	Nowe mutanty PRONGF i ich zastosowanie do wytwarzania BETA-NGF
WO2015038582A2 (en) *	2013-09-11	2015-03-19	New York University	Methods and compositions for treating bone diseases
EP3406259A1 (en)	2017-05-24	2018-11-28	Dompé farmaceutici S.p.A.	Neurotrophins for use in the treatment of hearing loss
CN108456681B (zh) *	2018-03-26	2019-10-11	江苏中新医药有限公司	高效表达重组人神经生长因子的基因组合
EP3784691B1 (en)	2018-04-27	2026-03-25	Chiesi Farmaceutici S.p.A.	Production of nerve growth factor (ngf) and of muteins thereof
CN112334151A (zh) *	2018-06-29	2021-02-05	学校法人同志社	包含恩利卡生的制剂
EP3852785A1 (en)	2018-09-17	2021-07-28	Chiesi Farmaceutici S.p.A.	Agent for treatment of dermatological disorders
IT201900014646A1 (it) *	2019-08-12	2021-02-12	Consiglio Nazionale Ricerche	Peptide neurotrofico resistente alle proteasi per il trattamento terapeutico di patologie neurodegenerative e/o cutanee
JP7558260B2 (ja)	2019-09-17	2024-09-30	キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ	眼科障害の処置または防止における使用のための薬剤
IL302317A (en)	2020-10-28	2023-06-01	Dompe Farm Spa	Pharmaceutical packaging including polypropylene containers and aqueous formulations of NGF packed in them
EP4039269A1 (en)	2021-02-05	2022-08-10	Dompe' Farmaceutici S.P.A.	Ngf isoform for use in the treatment of ocular pathologies
WO2022221351A1 (en)	2021-04-13	2022-10-20	Dompé Farmaceutici S.P.A.	Treatment of neuropathic corneal pain with ngf
EP4311554A1 (en)	2022-07-29	2024-01-31	Dompé farmaceutici S.p.a.	Combination for use in ophthalmology
EP4316505A1 (en)	2022-08-05	2024-02-07	Dompé farmaceutici S.p.a.	Intranasal administration of ngf for the treatment of sensorineural hearing loss
EP4342485A1 (en)	2022-09-23	2024-03-27	Dompe' Farmaceutici S.P.A.	Ngf for the treatment of spasticity
EP4497431A1 (en)	2023-07-27	2025-01-29	Dompé farmaceutici S.p.A.	Pharmaceutical formulation comprising nerve growth factor
EP4623927A1 (en)	2024-03-27	2025-10-01	Dompe' Farmaceutici SpA	Ngf for use in the prevention or treatment of motor impairment caused by neonatal hypoxic-ischemic encephalopathy
EP4659759A1 (en)	2024-06-04	2025-12-10	Dompé farmaceutici SpA	Administration of ngf for the treatment of niemann-pick type c disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4139000A1 (de) *	1991-11-27	1993-06-03	Boehringer Mannheim Gmbh	Verfahren zur gentechnologischen herstellung von biologisch aktivem ss-ngf
WO1998010785A1 (en) *	1996-09-13	1998-03-19	Advanced Medicine Research Institute	Ophthalmic compositions of neurotrophic factors, remedies for optic nerve function disorders and method for treating optic nerve function disorders
ATE257514T1 (de) *	1998-10-09	2004-01-15	Scil Proteins Gmbh	Verfahren zur gewinnung von aktivem beta-ngf
US20030040082A1 (en)	2001-02-16	2003-02-27	Mark Tuszynski	Mutant pro-neurotrophin with improved activity
AU2002259305A1 (en)	2001-05-25	2002-12-09	Cornell Research Foundation, Inc.	High affinity ligand for p75 neurotrophin receptor
DE10360483B4 (de)	2003-12-22	2007-11-15	Scil Proteins Gmbh	Expressionsvektor und dessen Verwendung
ES2315842T3 (es) *	2004-01-19	2009-04-01	Nsgene A/S	Celulas terapeuticas humanas que secretan factor de crecimiento nervioso.
US20080050776A1 (en) *	2006-05-26	2008-02-28	Kenneth Neet	Stable mutated pro nerve growth factors
CN101260398B (zh)	2007-03-07	2013-06-05	舒泰神（北京）生物制药股份有限公司	神经生长因子基因定位改造动物及其制备方法和应用
PL2672984T3 (pl)	2011-12-19	2015-10-30	Wacker Chemie Ag	Nowe mutanty PRONGF i ich zastosowanie do wytwarzania BETA-NGF

2012
- 2012-12-19 PL PL12805695T patent/PL2672984T3/pl unknown
- 2012-12-19 TR TR2018/02360T patent/TR201802360T4/tr unknown
- 2012-12-19 HU HUE12805695A patent/HUE027245T2/en unknown
- 2012-12-19 ES ES12805695.9T patent/ES2545701T3/es active Active
- 2012-12-19 SM SM20180097T patent/SMT201800097T1/it unknown
- 2012-12-19 EA EA201491155A patent/EA031333B1/ru unknown
- 2012-12-19 PT PT128056959T patent/PT2672984E/pt unknown
- 2012-12-19 NO NO15157320A patent/NO2907521T3/no unknown
- 2012-12-19 US US14/366,460 patent/US9617322B2/en active Active
- 2012-12-19 RS RS20150561A patent/RS54220B1/sr unknown
- 2012-12-19 SI SI201230289T patent/SI2672984T1/sl unknown
- 2012-12-19 MX MX2017012894A patent/MX370861B/es unknown
- 2012-12-19 ES ES15157320.1T patent/ES2657344T3/es active Active
- 2012-12-19 WO PCT/EP2012/076251 patent/WO2013092776A1/en not_active Ceased
- 2012-12-19 JP JP2014546588A patent/JP6039146B2/ja active Active
- 2012-12-19 EP EP12805695.9A patent/EP2672984B1/en active Active
- 2012-12-19 DK DK15157320.1T patent/DK2907521T3/en active
- 2012-12-19 CN CN201711352074.1A patent/CN109400693A/zh active Pending
- 2012-12-19 PL PL15157320T patent/PL2907521T3/pl unknown
- 2012-12-19 KR KR1020147019162A patent/KR101837802B1/ko active Active
- 2012-12-19 SG SG11201402585PA patent/SG11201402585PA/en unknown
- 2012-12-19 LT LTEP15157320.1T patent/LT2907521T/lt unknown
- 2012-12-19 KR KR1020167027254A patent/KR20160120788A/ko not_active Withdrawn
- 2012-12-19 CN CN201280062855.6A patent/CN104203264B/zh active Active
- 2012-12-19 SI SI201231212T patent/SI2907521T1/en unknown
- 2012-12-19 CA CA2859262A patent/CA2859262C/en active Active
- 2012-12-19 HR HRP20150900TT patent/HRP20150900T1/hr unknown
- 2012-12-19 EP EP15157320.1A patent/EP2907521B1/en active Active
- 2012-12-19 SG SG10201605028VA patent/SG10201605028VA/en unknown
- 2012-12-19 PT PT151573201T patent/PT2907521T/pt unknown
- 2012-12-19 BR BR112014014913-5A patent/BR112014014913B1/pt active IP Right Grant
- 2012-12-19 DK DK12805695.9T patent/DK2672984T3/en active
- 2012-12-19 RS RS20180159A patent/RS56893B1/sr unknown
- 2012-12-19 MX MX2014007317A patent/MX353074B/es active IP Right Grant
- 2012-12-19 HU HUE15157320A patent/HUE036265T2/hu unknown
- 2012-12-19 AU AU2012357052A patent/AU2012357052B2/en active Active
2014
- 2014-05-22 ZA ZA2014/03753A patent/ZA201403753B/en unknown
- 2014-06-15 IL IL233137A patent/IL233137A0/en active IP Right Grant
2015
- 2015-08-20 SM SM201500201T patent/SMT201500201B/xx unknown
- 2015-08-26 CY CY20151100747T patent/CY1117016T1/el unknown
- 2015-12-22 US US14/978,407 patent/US10308694B2/en active Active
2016
- 2016-11-03 JP JP2016215749A patent/JP6622683B2/ja active Active
2018
- 2018-02-21 CY CY20181100195T patent/CY1119926T1/el unknown
- 2018-02-21 HR HRP20180307TT patent/HRP20180307T1/hr unknown
- 2018-08-07 JP JP2018148261A patent/JP2019011330A/ja active Pending
- 2018-08-08 JP JP2018148957A patent/JP2019006781A/ja active Pending
2019
- 2019-04-05 US US16/376,969 patent/US20200031893A1/en active Pending

Also Published As

Publication number	Publication date
KR101837802B1 (ko)	2018-03-12
HRP20180307T1 (hr)	2018-03-23
LT2907521T (lt)	2018-05-10
RS56893B1 (sr)	2018-04-30
BR112014014913B1 (pt)	2020-12-01
SI2672984T1 (sl)	2015-11-30
DK2672984T3 (en)	2015-08-24
WO2013092776A1 (en)	2013-06-27
PT2672984E (pt)	2015-10-01
ES2545701T3 (es)	2015-09-15
AU2012357052A1 (en)	2014-07-24
CN104203264A (zh)	2014-12-10
SI2907521T1 (en)	2018-03-30
HUE027245T2 (en)	2016-10-28
MX2014007317A (es)	2014-11-25
JP2017071611A (ja)	2017-04-13
NZ627054A (en)	2015-06-26
KR20140103318A (ko)	2014-08-26
SG11201402585PA (en)	2014-10-30
EA201491155A1 (ru)	2015-01-30
EP2907521A1 (en)	2015-08-19
SMT201500201B (it)	2015-10-30
KR20160120788A (ko)	2016-10-18
CY1117016T1 (el)	2017-04-05
US10308694B2 (en)	2019-06-04
CY1119926T1 (el)	2018-12-12
HRP20150900T1 (hr)	2015-10-09
MX370861B (es)	2020-01-08
EP2907521B1 (en)	2017-11-22
EP2672984B1 (en)	2015-05-27
ZA201403753B (en)	2015-11-25
IL233137A0 (en)	2014-07-31
US9617322B2 (en)	2017-04-11
SG10201605028VA (en)	2016-07-28
CA2859262A1 (en)	2013-06-27
BR112014014913A2 (pt)	2017-06-13
CN104203264B (zh)	2018-08-28
HK1202055A1 (en)	2015-09-18
TR201802360T4 (tr)	2018-03-21
PT2907521T (pt)	2018-02-22
JP6039146B2 (ja)	2016-12-07
JP2019006781A (ja)	2019-01-17
RS54220B1 (sr)	2015-12-31
US20160244496A1 (en)	2016-08-25
EP2672984A1 (en)	2013-12-18
US20200031893A1 (en)	2020-01-30
NO2907521T3 (pl)	2018-04-21
HUE036265T2 (hu)	2018-06-28
JP2015501828A (ja)	2015-01-19
CA2859262C (en)	2021-04-06
SMT201800097T1 (it)	2018-03-08
JP2019011330A (ja)	2019-01-24
JP6622683B2 (ja)	2019-12-18
US20150087020A1 (en)	2015-03-26
MX353074B (es)	2017-12-19
CN109400693A (zh)	2019-03-01
PL2672984T3 (pl)	2015-10-30
AU2012357052B2 (en)	2015-06-25
DK2907521T3 (en)	2018-03-05
EA031333B1 (ru)	2018-12-28
ES2657344T3 (es)	2018-03-02

Publication	Publication Date	Title
HRP20180307T1 (hr)	2018-03-23	Novi mutanti prongf-a i njihova upotreba u proizvodnji beta-ngf-a
GB2488918B (en)	2014-03-05	Sugar mixtures and methods for production and use thereof
SG10201608870UA (en)	2016-12-29	Nanostructured articles and methods to make the same
SG11201404580QA (en)	2014-10-30	Nanostructured materials and methods of making the same
SG11201404488UA (en)	2014-08-28	Nanostructured materials and methods of making the same
PL2766682T3 (pl)	2017-03-31	Sposób, linia technologiczna i wykorzystanie linii technologicznej do wytwarzania cząstek liofilizowanych
IL230650A (en)	2016-12-29	Methylphenidate-drug-mediators and processes for their preparation and use
HUE042637T2 (hu)	2019-07-29	Laminátumok és azok elõállítására szolgáló módszerek
EP2652141A4 (en)	2014-05-14	MICROORGANISMS AND METHOD FOR PRODUCING 1,4-CYCLOHEXANDIMETHANOL
EP2697378A4 (en)	2014-10-01	IDENTIFICATION AND USE OF KRP MUTANTS IN PLANTS
EP2791075A4 (en)	2015-10-28	SYNTHETIC MARBLE HIGH HARDENING AND METHOD OF MANUFACTURING THEREOF
ZA201400558B (en)	2015-08-26	Methods for the production of a cosmetic composition comprising leukolectin and uses thereof
IL229432A0 (en)	2014-01-30	Chondroitin sulfate domi-shark and a process for its preparation
EP2649217A4 (en)	2014-11-26	ARTICLE AND METHOD FOR ITS MANUFACTURE AND USE
EP2654486A4 (en)	2015-01-07	STRUCTURED SURFACE WITH SEVERAL COLUMNS AND CAPS AND METHOD FOR THE PRODUCTION THEREOF
PT2864087T (pt)	2016-12-20	Material compósito de madeira com aerogéis e respetivo processo de produção e utilização
IL233354A (en)	2017-06-29	2, 6-Dihlo-5-Alkoxy-4-Converted-Pyrimidine, Pyrimidine-Carbaldehyde and Production and Use Methods
IL226234B (en)	2018-07-31	Nucleons, ribocapsids and methods for their production
ZA201308457B (en)	2015-02-25	Shark-like chondroitin sulphate and process for the preparation thereof
PL387453A1 (pl)	2010-09-13	Meble korkowe oraz sposób wytwarzania mebli korkowych
GB201016060D0 (en)	2010-11-10	Improvements in the measurement and control of process parameters
GB201215557D0 (en)	2012-10-17	Improvements in the manufacture of tiles